The OTC is starting to heat up, even though the bearish pressure hasn’t gone away. We’ve been here before and will be here again no matter what happens. Markets go in cycles and OTC stocks aren’t immune. Matter of fact, the OTC probably sees more bull and bear markets in a year than any other market.
When markets come out of bear markets, we get powerful bull moves. We are on the verge of seeing many 10x moves and opportunities.
In this article, we look at 4 OTC penny stocks to own, including Sysorex, Inc (OTCQB: SYSX), Tonner-One World Holdings, Inc (OTCPK: TONR), Regen BioPharma Inc (OTCPK: RGBP), and LiveToBeHappy, Inc (OTCPK: CAVR).
OTC Penny Stocks #1 SYSX
Sysorex, Inc has already surged over 740% over the month. At the beginning of May, we reiterated our bullish expectations on this OTCQB member, as the stock had been oversold for months. Last month, SYSX bottomed out near $0.005, and now it trades at $0.084, up about 1,600%. The stock demonstrates that investors can secure hefty profits even amid bearish markets and general uncertainty, and this is not an isolated example.
As you may know from our previous posts, SYSX has been focusing on mining Ethereum, the second-largest cryptocurrency out there. It has been the largest publicly-traded ETH mining and blockchain technology company, but investors have probably lost confidence given that Ethereum was adopting another consensus mechanism that will make mining obsolete.
While Ethereum’s full upgrade has been delayed, SYSX’s price rebound is related to a deal with Ostendo Technologies, Inc, on which we reported recently more in detail. Basically, it looks like a reverse merger deal that will see Ostendo benefiting from a great share structure.
Ostendo is a technology company that designed a Quantum Photonic Imager platform, purpose-built, to create next-generation, light field semiconductor chips and augmented reality hardware for consumer, enterprise, and defense applications.
In anticipation of the completion of the Ostendo transaction, SYSX is in active discussions with several New York City-based investment banks to assist with its anticipated uplisting to a national stock exchange.
SYSX used to trade above $5 last year, and it’s time to get back to those levels. For now, the stock has to consolidate above the next resistance at $0.14. Even after surging over 1,500% in less than a month and has already been a big winner for our readers, SYSX is available at a great price and still has much room for growth.
OTC Penny Stocks #2 TONR
Tonner-One World Holdings, Inc has had a great week, recovering from the lowest level since September 2021. The Pink Current stock has gained 57% during the last five sessions to consolidate above $0.001. TONR seems to have much room for growth given that it has been declining since the end of last year when it traded above the penny mark.
TONR is another crypto play that has been bleeding but can recover soon. Earlier this year, the company established a new division called the Digital Commerce Collective (DCC), which focuses on four key areas of growth: crypto and forex technology, interactive commerce, proprietary trading firm initiatives, and IP licensing for entertainment and Metaverse applications.
TONR is rolling out new phases of the DCC, with the first being the launch of TradeScore, a suite of crypto, forex, and market trading applications, which had received an official endorsement from the former CEO of Epic Trading, Spencer Iverson.
The second phase was the launch of collectible non-fungible tokens (NFTs), which were minted from an exclusive IP license with the Prettie Girls! line of toys, Stacey McBride-Irby, creator of So In Style® Barbie™, and celebrity doll designer Robert Tonner, who is best known for his dolls based on feature films like Harry Potter, Wonder Woman, Avatar, and Superman, among others.
A sneak peek at a few of the 10,000 Prettie Girls! NFTs Minting on April 15. Whitelist members will have first dibs at these Pretties today. There is still time to get your secure your spot at https://t.co/YRPIXJkFUL.$TONR pic.twitter.com/sqtBnVoJb4
— Tonner-One World Holdings, Inc (@TonnerOWInc) April 14, 2022
The next phase will be related to a proprietary trading firm called Forex Funding Group, which already has a dedicated website. We think the recent price spike has to do with this firm, as TONR said it would release major news on May 31.
We know everyone is looking forward to news from $TONR.
Its coming and will be well worth the wait.
Corinda J. Melton
— Tonner-One World Holdings, Inc (@TonnerOWInc) May 23, 2022
The chances are that the news is related to the trading firm, although TONR might have even more updates.
The fourth phase will be about animated short-length projects, feature films, and Metaverse applications involving the Prettie Girls! TONR’s entertainment subsidiary, Prettie Girls! Productions, has already completed several pitch projects for presentation to Netflix, Disney +, Hulu, and Prime Video.
Eventually, TONR is planning to develop its own cryptocurrency exchange and brokerage firm.
TONR’s roadmap is impressive, and the current bearish pressure has more to do with the bleeding crypto and stock markets rather than the company’s fundamentals. We expect this stock to come back even stronger.
OTC Penny Stocks #3 RGBP
Regen BioPharma Inc is a familiar stock for our subscribers and readers. The biotech company saw its share price gaining over 16% over the week, although it’s still early to anticipate the reversal of the long-term downtrend.
RGBP is now trading at only $0.0042, after bottoming out two weeks ago at $0.0036, which was the lowest level since the beginning of 2021. How much should RGBP holders endure? Well, we still think this Pink Current stock can provide great value in the long term, especially at this low price. Buying RGBP for less than a penny is the real deal, as the company can monetize its multiple patents.
RGBP is focused on the immunology and immunotherapy space. The company is working on molecule therapies for treating cancer and autoimmune disorders. On top of that, Regen is working on translational medicine platforms for the commercialization of stem cell therapies. RGBP produces stem-based medicines for diabetes, heart-related illness, circulatory issues, and Chronic Obstructive Pulmonary Disease. The stem cell industry is expected to exceed $15 billion by 2027.
As mentioned, RGBP sits on a pile of patents. Considering its extensive intellectual property portfolio, it is a matter of time before RGBP investors get rewarded. The company has 8 patents and more than 10 published applications and pending applications. The last four patents have been granted within the last 12 months. At least some of them should bring value to shareholders, and the fact that RGBP has a great share structure makes it an even better pick for your portfolio.
$rgbp $rgbpp Praying that one day they will change the world.https://t.co/V5nrnSK9oChttps://t.co/RBVc1wsue9 pic.twitter.com/vCeKc5QXVR
— Pu'ali (@Bettorbewise) May 24, 2022
OTC Penny Stocks #4 CAVR
LiveToBeHappy, Inc, formerly known as CAVU Resources Inc, continues to gain traction as the Pink Current stock is accelerating the recovery. CAVR bottomed out at the end of April near the penny mark, touching the lowest level since December 2020. It has extended by 60% since then, currently trading at $0.0162.
CAVR is a vertically integrated lifestyle and real estate services company.
Recently, the company released its financial results for the three months to March, which supported the price recovery.
The company’s revenues doubled year-over-year to $2.7 million, while gross profit rose 84% to $473k. CAVR has completed five acquisitions in Q4 2021.
CAVR CEO Kevin Vincent Cox commented:
“The five acquisitions we completed in late 2021 have already contributed to our financial performance, accounting for over 30% of our first quarter consolidated revenues. As we look forward to the remainder of 2022, we remain focused on evaluating and closing on other opportunities in our robust M&A pipeline while generating efficiencies in our current operating portfolio. We have built a strong foundation for our platform, from which we expect to build into a business that will ultimately generate sustainable, long-term value for our shareholders.”
For the current quarter, CAVR expects revenues of at least $11 million, up 307% from Q1. The figure is quite significant considering that the company’s market cap is at about $25 million.
CAVR is expanding its portfolio with more meaningful acquisitions and continues to attract institutional investors. A few weeks ago, the company announced that it had closed on the first tranche of funding from RB Capital Partners. The funds will be used to restructure the balance sheet, reduce the float of outstanding unrestricted common stock, complete diligence on two pending acquisitions, and provide working capital to grow and build on the lifestyle brands it acquired in 2021.
We think CAVR is going in the right direction, and shareholders won’t regret getting exposure to this stock in 2022.
THE FINAL NOTE
All of the 4 OTC stocks discussed today are good stocks to own. The upside is much greater than the downside at these levels.
It’s also very important to eye OTC stocks that have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two penny stocks to succeed in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.